| 货号 | 规格 | 价格 | 上海 | 北京 | 武汉 | 南京 | 购买数量 |
|---|---|---|---|---|---|---|---|
S85676-1mg |
98.00% | ￥180.00 | 8 | - | - | - |
|
S85676-2mg |
98.00% | ￥296.00 | 10 | - | - | - |
|
S85676-5mg |
98.00% | ￥450.00 | 10 | - | - | - |
|
S85676-10mg |
98.00% | ￥670.00 | >10 | - | - | - |
|
S85676-25mg |
98.00% | ￥1200.00 | 10 | - | - | - |
|
S85676-50mg |
98.00% | ￥1870.00 | 10 | - | - | - |
|
| 产品描述： | BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | HDAC4:MEF2;Apoptosis;HDAC | ||||||||||||||||||||
| 体内研究： | BML-210 (20 mg/kg; 腹腔给药; 每周 3 次，持续两周) 显着抑制肿瘤生长和重量。BML-210 对免疫缺陷裸鼠 (Nu/J) 的肿瘤生长和体重没有影响 | ||||||||||||||||||||
| 参考文献： | 1. Nimanthi Jayathilaka, et al. Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic Acids Res. 2012 Jul; 40(12): 5378–5388. 2. Veronika Borutinskaite, et al. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. Int J Mol Sci. 2015 Aug; 16(8): 18252–18269. 3. Zhuolong Zhou, et al. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng. 2021 Nov;5(11):1320-1335. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | 2-8℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京